Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened

Predictive Oncology Inc. (NASDAQ:POAI)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $7.41 and traded as low as $1.54. Predictive Oncology shares last traded at $1.57, with a volume of 34,209 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen lowered Predictive Oncology to a “strong sell” rating in a research report on Saturday, December 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Predictive Oncology Stock Down 2.5%

The company’s fifty day moving average price is $3.45 and its two-hundred day moving average price is $7.41. The company has a market cap of $5.33 million, a price-to-earnings ratio of -0.12 and a beta of 1.35.

About Predictive Oncology

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.